See the DrugPatentWatch profile for Amvuttra
What is Amvuttra and What Does it Treat?
Amvuttra is a medication used to treat polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults [1]. It is an RNA interference (RNAi) therapeutic that targets and silences the TTR gene, reducing the production of the TTR protein [1].
How Does Amvuttra Work?
Amvuttra works by targeting the messenger RNA (mRNA) of the transthyretin (TTR) gene. By binding to this mRNA, it prevents the liver from producing the abnormal TTR protein that accumulates in nerve and other tissues in patients with hATTR-PN [1]. This reduction in TTR protein aims to slow or halt the progression of the disease [1].
What is the Competitive Landscape for Amvuttra?
The market for hATTR-PN treatments includes other therapies that target TTR protein production or stabilize the TTR protein. These include Vyndaqel/Vyndamax (tafamidis), which stabilizes the TTR protein, and Tegsedi (inotersen) and Wayklist (pάζinirán), both RNAi therapies [1]. Amvuttra's positioning within this competitive landscape is influenced by its efficacy, safety profile, and administration route compared to these other treatments.
When Does Amvuttra's Patent Protection End?
Specific details regarding Amvuttra's patent expiry are not publicly available in this report. However, patent protection for pharmaceutical drugs is a critical factor in determining market exclusivity and the eventual entry of generic or biosimilar competitors. Information on drug patents and their expiry dates can often be found on resources like DrugPatentWatch.com [2].
What Clinical Data Supports Amvuttra's Use?
Amvuttra's efficacy and safety were evaluated in a clinical study where participants received Amvuttra or a placebo. The study demonstrated a statistically significant difference in the change from baseline in the modified polyneuropathy impact scale (NIS-LL) and the quality of life score (QOL-PN) between the Amvuttra and placebo groups, indicating a benefit for patients treated with Amvuttra [1].
Are There Any Concerns or Risks Associated with Amvuttra?
Amvuttra carries a risk of injection site reactions, which can be severe [1]. Common side effects observed in clinical trials included upper respiratory tract infections, reflux, and injection site reactions [1]. Patients are advised to discuss potential risks with their healthcare provider [1].
---
1. Amvuttra Prescribing Information. Approved by FDA. Available at: https://www.amvuttra.com/
2. DrugPatentWatch.com. Available at: https://www.drugpatentwatch.com/